{"schema_version":"1.0","type":"article","title":"Unmet Needs in MSS Colorectal Cancer and the Potential Role of HDAC Inhibition","url":"https://drugnews.com.tw/articles/2026-11-18-anbogen-abt301-mss-colorectal-hdac-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-18-anbogen-abt301-mss-colorectal-hdac-en.md","lang":"en","date":"2026-11-18","publish_at":"2026-11-18T08:00:00+08:00","updated_at":"2026-11-18","category":"商業分析系列","topic":"商業分析系列","tags":["HDAC","ABT-301","MSS","colorectal cancer"],"summary":"On October 19, 2026, the U.S. FDA granted accelerated approval to GSK's Jemperli (dostarlimab), based on AZUR-1 data, for adults with stage II/III locally advanced rectal cancer with deficient mismatch repair or high microsatellite instability (dMMR/MSI-H). Patients receive immunotherapy first. Those who achieve a clinical complete response may, after evaluation, be managed nonoperatively under close surveillance, potentially avoiding surgery and radiation while preserving the rectum. [1]","key_points":["On October 19, 2026, the U.S. FDA granted accelerated approval to GSK's Jemperli (dostarlimab), based on AZUR-1 data, for adults with stage II/III locally advanced rectal cancer with deficient mismatch repair or high microsatellite instability (dMMR/MSI-H). Patients receive immunotherapy first. Those who achieve a clinical complete response may, after evaluation, be managed nonoperatively under close surveillance, potentially avoiding surgery and radiation while preserving the rectum. [1]","This approval applies to locally advanced dMMR/MSI-H rectal cancer. A different and still largely unsolved challenge is metastatic colorectal cancer that is microsatellite stable and mismatch-repair proficient (MSS/pMMR). Over the past decade, major drugmakers have tested many immunotherapy combinations in this population, but only a handful have improved survival in Phase 3 trials.","That same month, ESMO 2026 delivered another signal: in a Phase 3 trial in advanced melanoma, an HDAC inhibitor plus a PD-1 antibody improved progression-free survival. The result adds a piece of evidence to the therapeutic strategy behind Anbogen Therapeutics' ABT-301 triplet and sharpens the central question: can this approach work in MSS colorectal cancer? [8]"],"facts":[],"sections":[],"references":[],"images":[],"cover_image":"https://drugnews.com.tw/assets/articles/anbogen-abt301-mss-colorectal-hdac-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-18）。Unmet Needs in MSS Colorectal Cancer and the Potential Role of HDAC Inhibition。https://drugnews.com.tw/articles/2026-11-18-anbogen-abt301-mss-colorectal-hdac-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{},"client_approved":true,"social":{"facebook":"【Unmet Needs in MSS Colorectal Cancer and the Potential Role of HDAC Inhibition】\n──────────\nCan HDAC Inhibition Help Close the Treatment Gap in MSS Colorectal Cancer?\n\nOn October 19, 2026, the U.S. FDA granted accelerated approval to GSK's Jemperli (dostarlimab), based on AZUR-1 data, for adults with stage II/III locally advanced rectal cancer with deficient mismatch repair or high microsatellite instability (dMMR/MSI-H). Patients receive immunotherapy first. Those who achieve a clinical complete response may, after evaluation, be managed nonoperatively under close surveillance, potentially avoiding surgery and radiation while preserving the rectum. [1]\n\nThis approval applies to locally advanced dMMR/MSI-H rectal cancer. A different and still largely unsolved challenge is metastatic colorectal cancer that is microsatellite stable and mismatch-repair proficient (MSS/pMMR). Over the past decade, major drugmakers have tested many immunotherapy combinations in this population, but only a handful have improved survival in Phase 3 trials.\n\nThat same month, ESMO 2026 delivered another signal: in a Phase 3 trial in advanced melanoma, an HDAC inhibitor plus a PD-1 antibody improved progression-free survival. The result adds a piece of evidence to the therapeutic strategy behind Anbogen Therapeutics' ABT-301 triplet and sharpens the central question: can this approach work in MSS colorectal cancer? [8]\n\n──────────\n\n📌【01 Why the Same Immunotherapy Needs a Different Combination】\n\ndMMR tumors cannot repair DNA properly. They accumulate more mutations and neoantigens, making them easier for the immune system to recognize. Once a PD-1 antibody releases the brake, T cells have a chance to attack.\n\nIn the FDA's review of AZUR-1, 154 patients received treatment. Among the 116 independently assessed, response-evaluable patients, 54 (47%) achieved a clinical complete response lasting 12 months. For people with rectal cancer, organ preservation can also reduce the effects of surgery and radiation on bowel, urinary, and reproductive function. A clinical complete response still requires follow-up confirmation and should not be treated as a cure. [1,22]\n\nMSS tumors face a different set of barriers. Many have fewer mutations and neoantigens, making immune recognition more difficult. Abnormal blood vessels and stroma may keep T cells out, while myeloid-derived suppressor cells and regulatory T cells dampen the immune response. Releasing the PD-1 brake alone is often not enough to get the system moving.\n\nThat does not mean Jemperli has failed in MSS disease. GSK is testing dostarlimab plus chemotherapy in resectable, locally advanced MSS colon cancer in AZUR-4. The same drug may require a different combination for a different tumor biology. [2]\n\nFigure 1. Stage II/III locally advanced dMMR/MSI-H rectal cancer now has an organ-preservation treatment pathway, while immunotherapy combinations remain under study in MSS/pMMR colorectal cancer. The disease stages and treatment goals are different. [1,2]\n\n──────────\n\n📌【02 Beyond Response Rate the Harder Hurdle Is Survival】\n\nWhen comparing representative trials, response rates and survival need to be considered alongside prior lines of therapy and the definitions and prevalence of liver metastases:\n\nTrial and phase｜Study regimen｜Prior treatment and liver metastases｜Objective response rate｜Median OS (months)\n\nREGONIVO Japan Phase 1b [3]｜regorafenib + nivolumab｜CRC cohort: ≥3 prior lines, 80% (20/25) Baseline liver metastases: 52% (13/25)｜MSS: 33% (8/24)｜Single-arm No cross-trial comparison\n\nU.S. Phase 2 [4]｜regorafenib + nivolumab｜Prior anticancer regimens: 2, 43%; ≥3, 53%* Baseline liver metastases: 67% (47/70)｜7% (5/70) All responders had no baseline liver metastases｜Single-arm No cross-trial comparison\n\nIMblaze370 Phase 3 [5]｜cobimetinib + atezolizumab vs. regorafenib｜≥2 prior systemic chemotherapy regimens Baseline liver metastases: 66% (121/183) vs. 66% (59/90)｜—｜8.87 vs. 8.51 HR 1.00\n\nLEAP-017 Phase 3 [6]｜lenvatinib + pembrolizumab vs. physician's choice｜Pooled: 2 prior lines, 51%; ≥3 lines, 46% Baseline liver metastases: 70% in each arm｜10.4% vs. 1.7%｜9.8 vs. 9.3 HR 0.83 Prespecified threshold not met\n\nSTELLAR-303 Phase 3 901 patients [7]｜zanzalintinib + atezolizumab vs. regorafenib｜Median 2 prior systemic therapy lines Active liver metastases: 59% (264/451) vs. 56% (254/450)｜—｜10.9 vs. 9.4 HR 0.80 Overall-population endpoint met\n\nC-800-01 Phase 1b expansion [9]｜botensilimab + balstilimab｜Multiple prior lines 123 patients without active liver metastases｜21% (26/123)｜Single-arm No cross-trial comparison\n\nTable notes: Patient populations, prior treatment, control arms, and data cutoffs differ across trials, precluding direct ranking. In the Japanese REGONIVO study, prior treatment and liver-metastasis percentages use all 25 patients with colorectal cancer as the denominator; ORR uses the 24 patients with MSS disease. A dash indicates a result not listed in this table.\n\n* The 43% and 53% in the U.S. Phase 2 study refer to prior anticancer treatment regimens, including neoadjuvant, adjuvant, and repeated regimens. They should not be equated directly with lines of therapy. The 51% and 46% in LEAP-017 are pooled across both arms.\n\nLiver metastases at baseline and active liver metastases are not interchangeable. Patients without active liver metastases may include those who have never had liver metastases and those whose previously treated liver metastases meet the study's stability criteria after local therapy. STELLAR-303 required the relevant local treatment to have occurred at least six months before enrollment, with no subsequent radiographic progression. C-800-01 also enrolled patients without active liver metastases. Each trial must be interpreted using its own definitions. [9,18]\n\nTogether, these studies offer three lessons:\n\nFirst, eye-catching results from a small trial may not be reproducible. REGONIVO's response rate fell sharply from the Japanese Phase 1 study to the U.S. Phase 2 study. Sample size, patient mix, and the prevalence of liver metastases differed between the trials, but the development lesson is clear: early numbers must be confirmed in larger populations that more closely resemble real-world practice.\n\nSecond, tumor shrinkage still has to translate into a survival benefit. LEAP-017 produced a numerically higher response rate, but not an OS improvement that crossed the prespecified statistical threshold. Grade 3 or higher treatment-related adverse events occurred in 58.4% of the combination arm versus 42.1% of the control arm. Developers have to evaluate efficacy and patient tolerability together. [6]\n\nThird, patient mix shapes how results should be interpreted. Some early studies with higher response rates had a lower prevalence of liver metastases or excluded patients with active liver metastases. These are important conditions for interpreting the results, not evidence that one combination is more effective than another. The botensilimab data came from a single-arm study in patients without active liver metastases. STELLAR-303 met its OS endpoint in the overall population, but the final analysis of the co-primary endpoint in patients without active liver metastases, reported in 2026, was not statistically significant. [7,9,17]\n\nCompetition is also moving across drug modalities. The PD-1/VEGF bispecific antibody ivonescimab is being paired with chemotherapy in the first-line setting, while the antibody-drug conjugate telisotuzumab adizutecan plus bevacizumab is being tested in later lines. [10,11]\n\nSTELLAR-303's Phase 3 survival evidence in the overall population is an important advance. But the trials differ in patients, lines of therapy, and control arms, so they should not be ranked by response rate or survival months. What the next generation of combinations must deliver is a reproducible response, durable disease control, and a regimen patients can stay on.\n\nFigure 2. Representative studies highlight the challenges MSS immunotherapy combinations face in response rate, survival, and patient selection. Liver-metastasis percentages follow each trial's definition and cannot support a direct ranking. The bars summarize reported values; they are not original survival curves. STELLAR-303 reports active liver metastases, while botensilimab plus balstilimab enrolled patients without active liver metastases. [3-7,9]\n\n──────────\n\n📌【03 New ESMO Evidence Takes HDAC Plus PD-1 into Phase 3 Validation】\n\nHDAC inhibitors have been marketed in hematologic malignancies for years. In solid tumors and immunotherapy combinations, however, development has repeatedly run into two questions: which tumors are the right fit, and can patients stay on treatment long enough?\n\nHBI-8000-303 was a randomized, double-blind, placebo-controlled Phase 3 trial in 404 patients with advanced melanoma. It compared HBI-8000 (tucidinostat/chidamide) plus nivolumab with placebo plus nivolumab. Enrollment primarily involved patients who had not received PD-1/PD-L1 inhibitors for advanced disease; this does not mean all patients were naive to every systemic therapy: [19,20]\n\n• Median progression-free survival (PFS): 11.7 versus 7.4 months; hazard ratio 0.73 [8]\n\n• Objective response rate (ORR): 41.4% (84/203) versus 32.3% (65/201), numerically higher but not statistically significant (p=0.0569) [19]\n\n• Grade 3/4 treatment-related adverse events: 54.8% versus 17.9%\n• A conference toxicity-discussion slide separately reported grade 5 adverse events (deaths) in 4/199 patients (2.01%) in the HBI-8000 arm. That line did not establish that all events were treatment-related or report the corresponding control-arm figure. [19,21]\n\n• HBI-8000 dose reductions were required in 37.6% (approximately 38%) of patients in the combination arm [23]\n\n• Overall survival data remain immature; durability of benefit and safety require further follow-up [23]\n\nThe PFS improvement provides randomized Phase 3 evidence that adding an HDAC inhibitor to PD-1 therapy can deliver incremental benefit in melanoma. The accompanying adverse events and dose reductions raise the next development question: once efficacy is added, can patients maintain a clinically useful treatment intensity?\n\nMelanoma is already more responsive to immunotherapy, so the role of an HDAC inhibitor there may be to accelerate a vehicle that is already moving. MSS colorectal cancer first has to get the vehicle started. HBI-8000 increases the credibility of the strategy, but ABT-301's benefit in MSS disease must still be established in its own human trial.\n\nFigure 3. HBI-8000-303 improved PFS in advanced melanoma while increasing grade 3/4 treatment-related adverse events and the need for dose reduction. A conference toxicity-discussion slide separately reported grade 5 adverse events in 4/199 patients (2.01%) in the HBI-8000 arm, without establishing that all events were treatment-related. The safety denominator of 199 differs from the ORR denominator of 203. Patients had not received PD-1/PD-L1 inhibitors for advanced disease. These are not efficacy results for ABT-301 in MSS disease; overall survival and safety require further follow-up. [8,19–21,23]\n\n──────────\n\n📌【04 Why Three Drugs Are Being Studied Together in a Cold Tumor】\n\nTo turn a cold tumor hot, researchers aim to address three problems at once: make the tumor visible, help T cells enter, and keep them active once they are inside. The ABT-301 triplet assigns a different role to each agent:\n\n1. ABT-301 (Imofinostat): an oral Class I/IIb HDAC inhibitor intended to increase tumor visibility and reduce immune suppression through epigenetic modulation.\n\n2. Bevacizumab: a VEGF inhibitor intended to improve the conditions for immune-cell entry through vascular modulation.\n\n3. Tislelizumab: a PD-1 antibody intended to release the T-cell brake.\n\nA randomized Phase 2 study in MSS colorectal cancer has provided an early signal for the HDAC-plus-PD-1-plus-antiangiogenic approach. CAPability-01 enrolled 48 patients. ORR was 44% (11/25) with the chidamide, sintilimab, and bevacizumab triplet versus 13% (3/23) with the chidamide and sintilimab doublet. The study also reported two treatment-related deaths. Because both arms contained an HDAC inhibitor, the comparison primarily signals the effect of adding antiangiogenic therapy; it cannot isolate the independent contribution of HDAC inhibition. [12]\n\nA mechanistic study in Cancer Discovery provides a further biological rationale for the triplet. While chidamide enhances CD8 T-cell activity, it may also induce tumor-associated macrophages to secrete VEGFA, creating a resistance pathway. That makes antiangiogenic therapy a rational combination partner. [13]\n\nABT-301 also has animal evidence: a CT26 mouse study disclosed in a public patent supports studying ABT-301 with the anti-PD-L1 antibody avelumab. These are patent-disclosed mouse results for a doublet, not evidence of human efficacy for the ABT-301, tislelizumab, and bevacizumab triplet. [16]\n\nTogether, the clinical and animal signals narrow Anbogen's task to two questions: at a dose patients can tolerate, can ABT-301 produce meaningful immune modulation, and can those effects translate into durable clinical benefit?\n\nFigure 4. ABT-301, VEGF inhibition, and PD-1 blockade target epigenetics, the vascular environment, and the immune checkpoint, respectively. Their order illustrates the research rationale, not the sequence of drug administration. The arrows represent a research hypothesis; clinical benefit in humans remains to be demonstrated. [12-15]\n\n──────────\n\n📌【05 ABT-301 Focuses on Once Daily Dosing and Further Dose Optimization】\n\nThe Phase I/II trial of the ABT-301 triplet (NCT07244705) enrolls patients with locally advanced or metastatic pMMR/non-MSI-H colorectal cancer. The public registry specifies at least two prior lines of systemic therapy. Part 1 is designed to identify a safe dose; Part 2 will optimize dosing while evaluating preliminary activity. [14,15]\n\nOn October 5, Anbogen disclosed Part 1 progress through September 30: [14]\n\n1. Across the 50 mg and 100 mg once-daily (QD) cohorts, 10 patients were treated and no dose-limiting toxicities (DLTs) were observed.\n\n2. Based on safety and pharmacokinetics, the company selected QD dosing and advanced to a 150 mg QD cohort.\n\nSafety and pharmacokinetic findings supported the company's decision to focus development on once-daily dosing. These were small, nonrandomized dose cohorts, and the DLT window primarily covered the first 21 days. The findings therefore cannot establish comparative long-term safety. The next challenge is to connect the exposure needed for immune modulation with a dose patients can sustain. [15]\n\nAccording to the public trial registry, Part 2 will compare two doses or dosing regimens and assess activity and tolerability. The specific start date and progress at study sites remain subject to subsequent company announcements and registry updates. [15]\n\nPart 2 will have to answer the same questions posed to every combination discussed in Section 2: can responses be reproduced in a clearly defined population, can disease control last long enough, and can patients maintain the dose? Data worth reviewing together will include the response-rate denominator, the proportion of patients with liver metastases, duration of response, and rates of dose reduction and discontinuation. Results also need to distinguish liver metastases at baseline from active liver metastases. The public registry does not categorically exclude liver metastases, but the actual proportion of enrolled patients with liver metastases must be confirmed from trial data. [15]\n\nFigure 5. Based on information posted on Anbogen's website on October 5, 2026, QD dosing is the development path forward. Part 2 is the subsequent dose-optimization stage; this article does not assume a start date. Dose selection is a step toward clinical validation, not an efficacy conclusion. [14,15]\n\nJemperli gives eligible patients with stage II/III dMMR/MSI-H rectal cancer a chance to preserve the organ, while MSS/pMMR colorectal cancer still needs more options capable of changing outcomes. The Phase 3 melanoma result adds clinical support for combining HDAC inhibition with immunotherapy. In cold tumors, the next competition will be over durable benefit and a treatment intensity patients can maintain. Based on public updates, ABT-301 has focused development on QD dosing, advanced a 150 mg cohort, and planned further dose optimization. Its ability to generate reproducible human evidence will determine its position in the MSS combination landscape.\n\nThis article is an industry and company analysis. It does not constitute investment or medical advice.\n\n──────────\n\n📌【References】\n\n1. FDA. Dostarlimab accelerated approval: locally advanced rectal cancer. 2026-10-19.\n\n2. ClinicalTrials.gov. AZUR-4 (NCT06567782).\n\n3. REGONIVO. Journal of Clinical Oncology. 2020.\n\n4. Regorafenib plus nivolumab: U.S. Phase 2 study. 2023.\n\n5. IMblaze370. The Lancet Oncology. 2019.\n\n6. LEAP-017. Journal of Clinical Oncology. 2024.\n\n7. Hecht JR, et al. STELLAR-303: zanzalintinib plus atezolizumab versus regorafenib. The Lancet. 2025.\n\n8. HUYABIO International. HBI-8000-303 Phase 3 announcement. 2026-10-23.\n\n9. Schlechter BL, et al. Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases. Clinical Cancer Research. 2026.\n\n10. Ivonescimab plus mFOLFOX6. ASCO 2026. Abstract 3576.\n\n11. Telisotuzumab adizutecan plus bevacizumab. Annals of Oncology. 2026.\n\n12. CAPability-01. Nature Medicine. 2024.\n\n13. Vascular Normalization Augments the Anti-tumor… Cancer Discovery. 2025.\n\n14. Anbogen Therapeutics. ABT-301 clinical update. 2026-10-05.\n\n15. ClinicalTrials.gov. ABT-301 (NCT07244705).\n\n16. Hsu TA, et al. Pharmaceutical kits and uses thereof for treating colorectal cancer. US20240277663A1. 2024.\n\n17. Exelixis. STELLAR-303 trial update. 2026-06-22.\n\n18. Saeed A, et al. STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer. Future Oncology. 2024.\n\n19. Khushalani NI. HBI-8000-303. ESMO 2026; LBA54. Slides reproduced by KOL Pulse.\n\n20. National Cancer Institute. HBI-8000 + nivolumab trial (NCI-2022-06408).\n\n21. Michielin O. LBA54 – RESULTS: TOXICITY. ESMO 2026. Slide photograph provided 2026-11-11.\n\n22. FDA. Jemperli prescribing information. 2026.\n\n23. ESMO Congress 2026. Melanoma session; LBA54.\n\n──────────\n👉 完整分析與圖表：https://drugnews.com.tw/articles/2026-11-18-anbogen-abt301-mss-colorectal-hdac-en.html","facebook_images":["cover.png","figure-01.png","figure-02.png","figure-03.png","figure-04.png","figure-05.png","table-01.png"],"threads":"【Unmet Needs in MSS Colorectal Cancer and the Potential Role of HDAC Inhibition】\n\nhttps://drugnews.com.tw/articles/2026-11-18-anbogen-abt301-mss-colorectal-hdac-en.html","threads_images":["cover.png","figure-02.png","figure-03.png","figure-04.png"],"linkedin":"Unmet Needs in MSS Colorectal Cancer and the Potential Role of HDAC Inhibition\n\nhttps://drugnews.com.tw/articles/2026-11-18-anbogen-abt301-mss-colorectal-hdac-en.html\n\n@[AnBogen Therapeutics](urn:li:organization:81540872)","x":"Unmet Needs in MSS Colorectal Cancer and the Potential Role of HDAC Inhibition\n\nhttps://drugnews.com.tw/articles/2026-11-18-anbogen-abt301-mss-colorectal-hdac-en.html","vocus":"HDAC 路線能補上 MSS 大腸癌的缺口嗎？\n\n2026 年 10 月 19 日，美國 FDA 加速核准 GSK 的 Jemperli（dostarlimab），依據 AZUR-1 資料，用於成人第 II／III 期錯配修復缺陷／微衛星高度不穩定（dMMR／MSI-H）的局部晚期直腸癌。病人先接受免疫治療，若達到臨床完全反應，經評估後可在密切追蹤下採取非手術管理，有機會不開刀、不放療，保住直腸。[1]\n\n這次核准針對的是局部晚期 dMMR／MSI-H 直腸癌；另一個尚待突破的戰場，是以微衛星穩定／錯配修復完整（MSS／pMMR）為主的轉移性大腸直腸癌。過去十年，大藥廠為這群病人試過許多免疫組合，能在三期改善存活的仍屈指可數。\n\n同一個月，ESMO 2026 傳來新訊號：在晚期黑色素瘤的三期試驗中，HDAC 抑制劑加上 PD-1 抗體，改善了無惡化存活期。這讓安邦生技 ABT-301 三聯療法押注的路線多了一塊證據，也讓問題更直接：這條路能不能在 MSS 大腸癌走通？[8]\n\n【01 同一支免疫藥為什麼需要不同的配方】\n\ndMMR 腫瘤修不好 DNA，突變多、新抗原多，免疫系統容易認出來。PD-1 抗體一旦解除剎車，T 細胞就有機會開始攻擊。\n\nFDA 審查 AZUR-1 時，共治療 154 人，其中以 116 名獨立審查可評估病人為分母，有 54 人（47%） 達到持續 12 個月的臨床完全反應。對直腸癌病人來說，器官保留的價值，也包括減少手術與放療對排便、泌尿及生殖功能的影響；臨床完全反應仍需追蹤確認，不能視為治癒。[1,22]\n\nMSS 腫瘤面對的是另一組障礙。許多腫瘤突變與新抗原較少，免疫系統不容易辨識；異常血管與基質可能把 T 細胞擋在外面，髓系抑制細胞與調節性 T 細胞則壓住免疫反應。只放開 PD-1 這一道剎車，往往還不足以讓車子動起來。\n\n這不代表 Jemperli 在 MSS 失敗了。GSK 正在 AZUR-4 試驗中，測試 dostarlimab 加化療用於可切除的局部晚期 MSS 結腸癌。同一支藥，面對不同腫瘤，就需要不同的配方。[2]\n\n圖1　第 II／III 期局部晚期 dMMR／MSI-H 直腸癌已有器官保留的治療路徑，MSS／pMMR 大腸直腸癌則持續探索免疫組合；兩者的疾病階段與療效目標不同。[1,2]\n\n【02 反應率之後更難跨過的是存活期】\n\n把幾個代表性試驗放在一起，除了反應率與存活，也要看治療線別及肝轉移的定義與比例：\n\n試驗與期別｜研究組合｜既往治療與肝轉移｜客觀反應率｜中位OS（月）\n\nREGONIVO 日本 Ib 期 [3]｜regorafenib＋nivolumab｜CRC組≥3線80%（20/25） 基線肝轉移52%（13/25）｜MSS 33% （8/24）｜單臂 不作跨試驗比較\n\n美國二期 [4]｜regorafenib＋nivolumab｜既往抗癌療程2種43%、≥3種53%＊ 基線肝轉移67%（47/70）｜7%（5/70） 反應者均無基線肝轉移｜單臂 不作跨試驗比較\n\nIMblaze370 三期 [5]｜cobimetinib＋atezolizumab 對regorafenib｜≥2種既往全身化療療程 基線肝轉移66%（121/183）對66%（59/90）｜—｜8.87 對8.51 HR 1.00\n\nLEAP-017 三期 [6]｜lenvatinib＋pembrolizumab 對醫師選擇治療｜全體既往2線51%、≥3線46% 基線肝轉移兩組均70%｜10.4% 對1.7%｜9.8 對9.3 HR 0.83 未達預設門檻\n\nSTELLAR-303 三期901人 [7]｜zanzalintinib＋atezolizumab 對regorafenib｜既往全身治療中位2線 活動性肝轉移59%（264/451）對56%（254/450）｜—｜10.9 對9.4 HR 0.80 整體族群達標\n\nC-800-01 Ib期擴大 [9]｜botensilimab＋balstilimab｜既往多線治療 無活動性肝轉移123人｜21% （26/123）｜單臂 不作跨試驗比較\n\n表註：各試驗的患者組成、既往治療、對照組及資料截點不同，不能直接排名。日本 REGONIVO 的治療線數與肝轉移分母為25名CRC患者，ORR分母則為24名MSS患者；—表示本表未列該項結果。\n\n＊美國二期的43%與53%為既往抗癌「療程」數，包含術前、術後及重複療程，不宜直接等同治療線數。LEAP-017的51%與46%為兩組合併後的比例。\n\n「基線有肝轉移」與「活動性肝轉移」不能互換。無活動性肝轉移可包含從未發生肝轉移，以及曾有肝轉移、經局部治療後符合研究穩定條件者。STELLAR-303要求相關局部治療距收案至少6個月且無後續影像惡化；C-800-01亦採無活動性肝轉移族群。各試驗仍須依自身定義解讀。[9,18]\n\n這組研究留下三個教訓：\n\n第一，小試驗的亮眼結果未必能重現。REGONIVO 從日本一期到美國二期，反應率差了一大截。兩邊的樣本量、患者組成與肝轉移比例都不同，但對開發者的提醒很清楚：早期數字必須在更大、更接近真實臨床的族群裡再證明一次。\n\n第二，腫瘤縮小之後，還要證明存活獲益。LEAP-017 的反應率數值提高，卻沒有轉成達到預設統計門檻的 OS 改善；合併組三級以上治療相關不良事件為 58.4%，對照組為 42.1%。開發者得把療效與病人的耐受性放在一起看。[6]\n\n第三，患者組成影響結果的解讀。部分反應率較高的早期研究，肝轉移比例較低，或排除了活動性肝轉移；這是解讀結果時的重要條件，不能視為不同組合療效高低的證明。botensilimab 的數字來自無活動性肝轉移的單臂研究；STELLAR-303 整體存活達標，但 2026 年公布的無活動性肝轉移共同主要終點最終分析未達統計顯著。[7,9,17]\n\n競爭也正在跨越不同的藥物型態：PD-1／VEGF 雙抗 ivonescimab 搭配化療進攻一線，ADC 藥物 telisotuzumab adizutecan 加 bevacizumab 則在後線測試。[10,11]\n\nSTELLAR-303 在整體族群取得三期存活證據，是這條路的重要進展。不同試驗的患者、治療線別與對照組各異，不宜按反應率或存活月數排名；下一代組合真正要爭取的，是能重現的反應、持久的疾病控制，以及病人維持得下去的療程。\n\n圖2　代表性研究凸顯 MSS 免疫組合在反應率、存活與患者選擇上的挑戰。肝轉移比例採各研究定義，不能直接排名；圖中橫條為摘要數值，不是原始存活曲線。STELLAR-303 的比例指活動性肝轉移，botensilimab＋balstilimab 納入無活動性肝轉移患者。[3–7,9]\n\n【03 ESMO新證據把HDAC加PD-1推進到三期驗證】\n\nHDAC 抑制劑在血液腫瘤已經上市多年，但進到實體腫瘤、和免疫治療搭配時，一直卡在兩件事：找對腫瘤，以及讓病人吃得夠久。\n\nHBI-8000-303 是隨機、雙盲、安慰劑對照的三期試驗，納入 404 名晚期黑色素瘤病人，比較 HBI-8000（tucidinostat／chidamide）加 nivolumab 與安慰劑加 nivolumab。收案以未在晚期疾病階段接受 PD-1／PD-L1 抑制劑者為主，並不等同所有病人都未曾接受任何全身治療：[19,20]\n\n• 中位無惡化存活期（PFS）：11.7 對 7.4 個月，風險比 0.73 [8]\n\n• 客觀反應率（ORR）：41.4%（84/203）對 32.3%（65/201），數值較高但未達統計顯著（p＝0.0569） [19]\n\n• 第 3／4 級治療相關不良事件：54.8% 對 17.9%\n• 會議毒性討論投影片另列 HBI-8000 組第 5 級不良事件（死亡）4/199（2.01%）；該行未標明所有事件的治療相關性，也未列出對照組相同數字。 [19,21]\n\n• 合併組有 37.6%（約38%）需要調降 HBI-8000 劑量 [23]\n\n• 整體存活資料尚未成熟，療效持續性與安全性仍需追蹤 [23]\n\nPFS 的改善，為 HDAC 加 PD-1 在黑色素瘤提供了隨機三期的增益證據。伴隨而來的不良事件與減量，則把開發問題推向下一層：療效加上去之後，病人能不能維持有用的治療強度。\n\n黑色素瘤本來就較容易對免疫治療產生反應，HDAC 抑制劑在這裡的角色，像是讓已經在跑的車再快一點；MSS 大腸癌卻需要先把車子發動。HBI-8000 提高了這條路線的可信度，ABT-301 在 MSS 的效益仍要由自己的人體試驗回答。\n\n圖3　HBI-8000-303 在晚期黑色素瘤改善 PFS，同時增加第 3／4 級治療相關不良事件與減量需求。會議毒性討論投影片另列 HBI-8000 組第5級不良事件4/199（2.01%），未標明全部事件的治療相關性；安全性分母199與ORR分母203不同。試驗治療背景為晚期疾病階段未接受 PD-1／PD-L1 抑制劑。這並非 ABT-301 在 MSS 的療效結果，整體存活與安全性仍需追蹤。[8,19–21,23]\n\n【04 冷腫瘤為什麼把三種藥放在一起研究】\n\n要把冷腫瘤變熱，研究者希望同時處理三件事：讓腫瘤被看見、讓 T 細胞進得去，以及讓 T 細胞進去後能持續作用。ABT-301 三聯療法依這個研究邏輯分工：\n\n1. ABT-301（Imofinostat）：口服 Class I／IIb HDAC 抑制劑，透過表觀遺傳調節，目標是提高腫瘤辨識度、減少免疫抑制。\n\n2. Bevacizumab：抑制 VEGF，藉由血管調節改善免疫細胞進入腫瘤的條件。\n\n3. Tislelizumab：PD-1 抗體，負責放開 T 細胞的剎車。\n\n「HDAC＋PD-1＋抗血管新生」已有 MSS 大腸癌的隨機二期線索。CAPability-01 共收 48 人：chidamide＋sintilimab＋bevacizumab 三聯組的反應率為 44%（11/25），chidamide＋sintilimab 雙聯組為 13%（3/23）；研究亦報告兩例治療相關死亡。兩組都含 HDAC 抑制劑，這項比較主要提供加入抗血管新生治療的線索，尚不能拆出 HDAC 的獨立貢獻。[12]\n\n《Cancer Discovery》的一項機制研究，進一步提出三聯的生物學理由：chidamide 增強 CD8 T 細胞作用的同時，也可能促使腫瘤相關巨噬細胞分泌 VEGFA，形成抵抗路徑；抗血管新生治療因而成為值得搭配的方向。[13]\n\nABT-301 本身也已有動物證據：公開專利的 CT26 小鼠研究，支持 ABT-301 與抗 PD-L1 抗體 avelumab 聯用的研究方向。這是專利披露的雙聯小鼠結果，並非 ABT-301、tislelizumab 與 bevacizumab 三聯在人體的療效。[16]\n\n上述臨床與動物研究的線索，把安邦需要回答的問題聚焦到兩件事：在病人能耐受的劑量下，ABT-301 能否產生有用的免疫調節，以及這些作用能否轉成持久的臨床效益。\n\n圖4　ABT-301、VEGF 抑制與 PD-1 抑制分別從表觀遺傳、血管環境與免疫檢查點切入。排列呈現研究邏輯，不代表實際給藥先後；箭頭為研究假說，人體臨床效益仍待驗證。[12–15]\n\n【05 ABT-301聚焦每日一次給藥與後續劑量優化】\n\nABT-301 三聯療法的 Phase I/II 試驗（NCT07244705），收治 pMMR／非 MSI-H 的局部晚期或轉移性大腸直腸癌病人，公開登錄列有至少接受過兩線全身治療的條件。Part 1 負責找出安全劑量，Part 2 則做劑量優化，同時觀察初步療效。[14,15]\n\n安邦 10 月 5 日公開了截至 9 月 30 日的 Part 1 進度：[14]\n\n1. 每日一次（QD）50 毫克與 100 毫克兩組共 10 人，未觀察到劑量限制性毒性（DLT）。\n\n2. 綜合安全性與藥物動力學，公司選擇 QD 給藥，推進到 150 毫克 QD 劑量組。\n\n依安全性與藥物動力學結果，公司把開發重心聚焦於每日一次給藥。這些是小樣本、非隨機的不同劑量組，且 DLT 主要觀察首 21 天，尚不能據此判定長期安全性優劣；接下來的關鍵，是把免疫調節需要的暴露量，和病人維持得下去的劑量接起來。[15]\n\n依公開試驗登錄，Part 2 將比較兩個劑量或給藥方案，評估活性與耐受性。具體啟動時程與試驗中心進度，仍應以公司後續公告及更新登錄為準。[15]\n\nPart 2 要交出的答案，就是第二節那些研究中每個組合都被問過的問題：反應能不能在清楚定義的族群中重現、疾病控制能不能維持夠久、病人能不能維持劑量。屆時值得一起看的數據包括反應率的分母、肝轉移比例、反應持續時間，以及減量與停藥情形。 解讀結果時也須區分「基線有肝轉移」與「活動性肝轉移」；公開登錄未將肝轉移一律列為排除條件，但實際收案比例仍須由試驗資料確認。[15]\n\n圖5　依安邦 2026 年 10 月 5 日官網公開資訊，QD 給藥是後續開發方向；Part 2 為後續劑量優化階段，不在本文預設啟動日期。劑量選擇是通往臨床驗證的步驟，尚非療效結論。[14,15]\n\nJemperli 讓符合條件的第 II／III 期 dMMR／MSI-H 直腸癌病人有機會保住器官，MSS／pMMR 大腸癌則仍需要更多能改變治療結果的選項。黑色素瘤的三期結果，讓 HDAC 與免疫治療的組合多了臨床依據；接下來在冷腫瘤的競爭，比的是持久獲益與可維持的治療強度。依已公開進度，ABT-301 已把給藥方向聚焦到 QD，推進 150 毫克劑量組，並規劃後續優化；能否拿出可重現的人體證據，將決定它在 MSS 聯合療法版圖中的位置。\n\n本文為產業與公司分析，不構成投資或醫療建議。\n\n【參考資料】\n\n1. FDA。Dostarlimab 局部晚期直腸癌加速核准公告。2026-10-19。\n\n2. ClinicalTrials.gov。AZUR-4（NCT06567782）。\n\n3. REGONIVO. Journal of Clinical Oncology. 2020.\n\n4. Regorafenib plus nivolumab: U.S. Phase 2 study. 2023.\n\n5. IMblaze370. The Lancet Oncology. 2019.\n\n6. LEAP-017. Journal of Clinical Oncology. 2024.\n\n7. Hecht JR, et al. STELLAR-303: zanzalintinib plus atezolizumab versus regorafenib. The Lancet. 2025.\n\n8. HUYABIO International。HBI-8000-303 三期公告。2026-10-23。\n\n9. Schlechter BL, et al. Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases. Clinical Cancer Research. 2026.\n\n10. Ivonescimab plus mFOLFOX6. ASCO 2026. Abstract 3576.\n\n11. Telisotuzumab adizutecan plus bevacizumab. Annals of Oncology. 2026.\n\n12. CAPability-01. Nature Medicine. 2024.\n\n13. Vascular Normalization Augments the Anti-tumor… Cancer Discovery. 2025.\n\n14. 安邦生技。ABT-301 臨床進度公告。2026-10-05。\n\n15. ClinicalTrials.gov。ABT-301（NCT07244705）。\n\n16. Hsu TA, et al. Pharmaceutical kits and uses thereof for treating colorectal cancer. US20240277663A1. 2024.\n\n17. Exelixis。STELLAR-303 試驗更新。2026-06-22。\n\n18. Saeed A, et al. STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer. Future Oncology. 2024.\n\n19. Khushalani NI。HBI-8000-303。ESMO 2026；LBA54。KOL Pulse 投影片轉載。\n\n20. National Cancer Institute。HBI-8000＋nivolumab 試驗（NCI-2022-06408）。\n\n21. Michielin O。LBA54 – RESULTS: TOXICITY。ESMO 2026。現場投影片照片（2026-11-11 提供）。\n\n22. FDA。Jemperli 藥品仿單。2026。\n\n23. ESMO Congress 2026。黑色素瘤場次；LBA54。","dcard":"HDAC 路線能補上 MSS 大腸癌的缺口嗎？\n\n2026 年 10 月 19 日，美國 FDA 加速核准 GSK 的 Jemperli（dostarlimab），依據 AZUR-1 資料，用於成人第 II／III 期錯配修復缺陷／微衛星高度不穩定（dMMR／MSI-H）的局部晚期直腸癌。病人先接受免疫治療，若達到臨床完全反應，經評估後可在密切追蹤下採取非手術管理，有機會不開刀、不放療，保住直腸。[1]\n\n這次核准針對的是局部晚期 dMMR／MSI-H 直腸癌；另一個尚待突破的戰場，是以微衛星穩定／錯配修復完整（MSS／pMMR）為主的轉移性大腸直腸癌。過去十年，大藥廠為這群病人試過許多免疫組合，能在三期改善存活的仍屈指可數。\n\n同一個月，ESMO 2026 傳來新訊號：在晚期黑色素瘤的三期試驗中，HDAC 抑制劑加上 PD-1 抗體，改善了無惡化存活期。這讓安邦生技 ABT-301 三聯療法押注的路線多了一塊證據，也讓問題更直接：這條路能不能在 MSS 大腸癌走通？[8]\n\n【01 同一支免疫藥為什麼需要不同的配方】\n\ndMMR 腫瘤修不好 DNA，突變多、新抗原多，免疫系統容易認出來。PD-1 抗體一旦解除剎車，T 細胞就有機會開始攻擊。\n\nFDA 審查 AZUR-1 時，共治療 154 人，其中以 116 名獨立審查可評估病人為分母，有 54 人（47%） 達到持續 12 個月的臨床完全反應。對直腸癌病人來說，器官保留的價值，也包括減少手術與放療對排便、泌尿及生殖功能的影響；臨床完全反應仍需追蹤確認，不能視為治癒。[1,22]\n\nMSS 腫瘤面對的是另一組障礙。許多腫瘤突變與新抗原較少，免疫系統不容易辨識；異常血管與基質可能把 T 細胞擋在外面，髓系抑制細胞與調節性 T 細胞則壓住免疫反應。只放開 PD-1 這一道剎車，往往還不足以讓車子動起來。\n\n這不代表 Jemperli 在 MSS 失敗了。GSK 正在 AZUR-4 試驗中，測試 dostarlimab 加化療用於可切除的局部晚期 MSS 結腸癌。同一支藥，面對不同腫瘤，就需要不同的配方。[2]\n\n圖1　第 II／III 期局部晚期 dMMR／MSI-H 直腸癌已有器官保留的治療路徑，MSS／pMMR 大腸直腸癌則持續探索免疫組合；兩者的疾病階段與療效目標不同。[1,2]\n\n【02 反應率之後更難跨過的是存活期】\n\n把幾個代表性試驗放在一起，除了反應率與存活，也要看治療線別及肝轉移的定義與比例：\n\n試驗與期別｜研究組合｜既往治療與肝轉移｜客觀反應率｜中位OS（月）\n\nREGONIVO 日本 Ib 期 [3]｜regorafenib＋nivolumab｜CRC組≥3線80%（20/25） 基線肝轉移52%（13/25）｜MSS 33% （8/24）｜單臂 不作跨試驗比較\n\n美國二期 [4]｜regorafenib＋nivolumab｜既往抗癌療程2種43%、≥3種53%＊ 基線肝轉移67%（47/70）｜7%（5/70） 反應者均無基線肝轉移｜單臂 不作跨試驗比較\n\nIMblaze370 三期 [5]｜cobimetinib＋atezolizumab 對regorafenib｜≥2種既往全身化療療程 基線肝轉移66%（121/183）對66%（59/90）｜—｜8.87 對8.51 HR 1.00\n\nLEAP-017 三期 [6]｜lenvatinib＋pembrolizumab 對醫師選擇治療｜全體既往2線51%、≥3線46% 基線肝轉移兩組均70%｜10.4% 對1.7%｜9.8 對9.3 HR 0.83 未達預設門檻\n\nSTELLAR-303 三期901人 [7]｜zanzalintinib＋atezolizumab 對regorafenib｜既往全身治療中位2線 活動性肝轉移59%（264/451）對56%（254/450）｜—｜10.9 對9.4 HR 0.80 整體族群達標\n\nC-800-01 Ib期擴大 [9]｜botensilimab＋balstilimab｜既往多線治療 無活動性肝轉移123人｜21% （26/123）｜單臂 不作跨試驗比較\n\n表註：各試驗的患者組成、既往治療、對照組及資料截點不同，不能直接排名。日本 REGONIVO 的治療線數與肝轉移分母為25名CRC患者，ORR分母則為24名MSS患者；—表示本表未列該項結果。\n\n＊美國二期的43%與53%為既往抗癌「療程」數，包含術前、術後及重複療程，不宜直接等同治療線數。LEAP-017的51%與46%為兩組合併後的比例。\n\n「基線有肝轉移」與「活動性肝轉移」不能互換。無活動性肝轉移可包含從未發生肝轉移，以及曾有肝轉移、經局部治療後符合研究穩定條件者。STELLAR-303要求相關局部治療距收案至少6個月且無後續影像惡化；C-800-01亦採無活動性肝轉移族群。各試驗仍須依自身定義解讀。[9,18]\n\n這組研究留下三個教訓：\n\n第一，小試驗的亮眼結果未必能重現。REGONIVO 從日本一期到美國二期，反應率差了一大截。兩邊的樣本量、患者組成與肝轉移比例都不同，但對開發者的提醒很清楚：早期數字必須在更大、更接近真實臨床的族群裡再證明一次。\n\n第二，腫瘤縮小之後，還要證明存活獲益。LEAP-017 的反應率數值提高，卻沒有轉成達到預設統計門檻的 OS 改善；合併組三級以上治療相關不良事件為 58.4%，對照組為 42.1%。開發者得把療效與病人的耐受性放在一起看。[6]\n\n第三，患者組成影響結果的解讀。部分反應率較高的早期研究，肝轉移比例較低，或排除了活動性肝轉移；這是解讀結果時的重要條件，不能視為不同組合療效高低的證明。botensilimab 的數字來自無活動性肝轉移的單臂研究；STELLAR-303 整體存活達標，但 2026 年公布的無活動性肝轉移共同主要終點最終分析未達統計顯著。[7,9,17]\n\n競爭也正在跨越不同的藥物型態：PD-1／VEGF 雙抗 ivonescimab 搭配化療進攻一線，ADC 藥物 telisotuzumab adizutecan 加 bevacizumab 則在後線測試。[10,11]\n\nSTELLAR-303 在整體族群取得三期存活證據，是這條路的重要進展。不同試驗的患者、治療線別與對照組各異，不宜按反應率或存活月數排名；下一代組合真正要爭取的，是能重現的反應、持久的疾病控制，以及病人維持得下去的療程。\n\n圖2　代表性研究凸顯 MSS 免疫組合在反應率、存活與患者選擇上的挑戰。肝轉移比例採各研究定義，不能直接排名；圖中橫條為摘要數值，不是原始存活曲線。STELLAR-303 的比例指活動性肝轉移，botensilimab＋balstilimab 納入無活動性肝轉移患者。[3–7,9]\n\n【03 ESMO新證據把HDAC加PD-1推進到三期驗證】\n\nHDAC 抑制劑在血液腫瘤已經上市多年，但進到實體腫瘤、和免疫治療搭配時，一直卡在兩件事：找對腫瘤，以及讓病人吃得夠久。\n\nHBI-8000-303 是隨機、雙盲、安慰劑對照的三期試驗，納入 404 名晚期黑色素瘤病人，比較 HBI-8000（tucidinostat／chidamide）加 nivolumab 與安慰劑加 nivolumab。收案以未在晚期疾病階段接受 PD-1／PD-L1 抑制劑者為主，並不等同所有病人都未曾接受任何全身治療：[19,20]\n\n• 中位無惡化存活期（PFS）：11.7 對 7.4 個月，風險比 0.73 [8]\n\n• 客觀反應率（ORR）：41.4%（84/203）對 32.3%（65/201），數值較高但未達統計顯著（p＝0.0569） [19]\n\n• 第 3／4 級治療相關不良事件：54.8% 對 17.9%\n• 會議毒性討論投影片另列 HBI-8000 組第 5 級不良事件（死亡）4/199（2.01%）；該行未標明所有事件的治療相關性，也未列出對照組相同數字。 [19,21]\n\n• 合併組有 37.6%（約38%）需要調降 HBI-8000 劑量 [23]\n\n• 整體存活資料尚未成熟，療效持續性與安全性仍需追蹤 [23]\n\nPFS 的改善，為 HDAC 加 PD-1 在黑色素瘤提供了隨機三期的增益證據。伴隨而來的不良事件與減量，則把開發問題推向下一層：療效加上去之後，病人能不能維持有用的治療強度。\n\n黑色素瘤本來就較容易對免疫治療產生反應，HDAC 抑制劑在這裡的角色，像是讓已經在跑的車再快一點；MSS 大腸癌卻需要先把車子發動。HBI-8000 提高了這條路線的可信度，ABT-301 在 MSS 的效益仍要由自己的人體試驗回答。\n\n圖3　HBI-8000-303 在晚期黑色素瘤改善 PFS，同時增加第 3／4 級治療相關不良事件與減量需求。會議毒性討論投影片另列 HBI-8000 組第5級不良事件4/199（2.01%），未標明全部事件的治療相關性；安全性分母199與ORR分母203不同。試驗治療背景為晚期疾病階段未接受 PD-1／PD-L1 抑制劑。這並非 ABT-301 在 MSS 的療效結果，整體存活與安全性仍需追蹤。[8,19–21,23]\n\n【04 冷腫瘤為什麼把三種藥放在一起研究】\n\n要把冷腫瘤變熱，研究者希望同時處理三件事：讓腫瘤被看見、讓 T 細胞進得去，以及讓 T 細胞進去後能持續作用。ABT-301 三聯療法依這個研究邏輯分工：\n\n1. ABT-301（Imofinostat）：口服 Class I／IIb HDAC 抑制劑，透過表觀遺傳調節，目標是提高腫瘤辨識度、減少免疫抑制。\n\n2. Bevacizumab：抑制 VEGF，藉由血管調節改善免疫細胞進入腫瘤的條件。\n\n3. Tislelizumab：PD-1 抗體，負責放開 T 細胞的剎車。\n\n「HDAC＋PD-1＋抗血管新生」已有 MSS 大腸癌的隨機二期線索。CAPability-01 共收 48 人：chidamide＋sintilimab＋bevacizumab 三聯組的反應率為 44%（11/25），chidamide＋sintilimab 雙聯組為 13%（3/23）；研究亦報告兩例治療相關死亡。兩組都含 HDAC 抑制劑，這項比較主要提供加入抗血管新生治療的線索，尚不能拆出 HDAC 的獨立貢獻。[12]\n\n《Cancer Discovery》的一項機制研究，進一步提出三聯的生物學理由：chidamide 增強 CD8 T 細胞作用的同時，也可能促使腫瘤相關巨噬細胞分泌 VEGFA，形成抵抗路徑；抗血管新生治療因而成為值得搭配的方向。[13]\n\nABT-301 本身也已有動物證據：公開專利的 CT26 小鼠研究，支持 ABT-301 與抗 PD-L1 抗體 avelumab 聯用的研究方向。這是專利披露的雙聯小鼠結果，並非 ABT-301、tislelizumab 與 bevacizumab 三聯在人體的療效。[16]\n\n上述臨床與動物研究的線索，把安邦需要回答的問題聚焦到兩件事：在病人能耐受的劑量下，ABT-301 能否產生有用的免疫調節，以及這些作用能否轉成持久的臨床效益。\n\n圖4　ABT-301、VEGF 抑制與 PD-1 抑制分別從表觀遺傳、血管環境與免疫檢查點切入。排列呈現研究邏輯，不代表實際給藥先後；箭頭為研究假說，人體臨床效益仍待驗證。[12–15]\n\n【05 ABT-301聚焦每日一次給藥與後續劑量優化】\n\nABT-301 三聯療法的 Phase I/II 試驗（NCT07244705），收治 pMMR／非 MSI-H 的局部晚期或轉移性大腸直腸癌病人，公開登錄列有至少接受過兩線全身治療的條件。Part 1 負責找出安全劑量，Part 2 則做劑量優化，同時觀察初步療效。[14,15]\n\n安邦 10 月 5 日公開了截至 9 月 30 日的 Part 1 進度：[14]\n\n1. 每日一次（QD）50 毫克與 100 毫克兩組共 10 人，未觀察到劑量限制性毒性（DLT）。\n\n2. 綜合安全性與藥物動力學，公司選擇 QD 給藥，推進到 150 毫克 QD 劑量組。\n\n依安全性與藥物動力學結果，公司把開發重心聚焦於每日一次給藥。這些是小樣本、非隨機的不同劑量組，且 DLT 主要觀察首 21 天，尚不能據此判定長期安全性優劣；接下來的關鍵，是把免疫調節需要的暴露量，和病人維持得下去的劑量接起來。[15]\n\n依公開試驗登錄，Part 2 將比較兩個劑量或給藥方案，評估活性與耐受性。具體啟動時程與試驗中心進度，仍應以公司後續公告及更新登錄為準。[15]\n\nPart 2 要交出的答案，就是第二節那些研究中每個組合都被問過的問題：反應能不能在清楚定義的族群中重現、疾病控制能不能維持夠久、病人能不能維持劑量。屆時值得一起看的數據包括反應率的分母、肝轉移比例、反應持續時間，以及減量與停藥情形。 解讀結果時也須區分「基線有肝轉移」與「活動性肝轉移」；公開登錄未將肝轉移一律列為排除條件，但實際收案比例仍須由試驗資料確認。[15]\n\n圖5　依安邦 2026 年 10 月 5 日官網公開資訊，QD 給藥是後續開發方向；Part 2 為後續劑量優化階段，不在本文預設啟動日期。劑量選擇是通往臨床驗證的步驟，尚非療效結論。[14,15]\n\nJemperli 讓符合條件的第 II／III 期 dMMR／MSI-H 直腸癌病人有機會保住器官，MSS／pMMR 大腸癌則仍需要更多能改變治療結果的選項。黑色素瘤的三期結果，讓 HDAC 與免疫治療的組合多了臨床依據；接下來在冷腫瘤的競爭，比的是持久獲益與可維持的治療強度。依已公開進度，ABT-301 已把給藥方向聚焦到 QD，推進 150 毫克劑量組，並規劃後續優化；能否拿出可重現的人體證據，將決定它在 MSS 聯合療法版圖中的位置。\n\n本文為產業與公司分析，不構成投資或醫療建議。\n\n【參考資料】\n\n1. FDA。Dostarlimab 局部晚期直腸癌加速核准公告。2026-10-19。\n\n2. ClinicalTrials.gov。AZUR-4（NCT06567782）。\n\n3. REGONIVO. Journal of Clinical Oncology. 2020.\n\n4. Regorafenib plus nivolumab: U.S. Phase 2 study. 2023.\n\n5. IMblaze370. The Lancet Oncology. 2019.\n\n6. LEAP-017. Journal of Clinical Oncology. 2024.\n\n7. Hecht JR, et al. STELLAR-303: zanzalintinib plus atezolizumab versus regorafenib. The Lancet. 2025.\n\n8. HUYABIO International。HBI-8000-303 三期公告。2026-10-23。\n\n9. Schlechter BL, et al. Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases. Clinical Cancer Research. 2026.\n\n10. Ivonescimab plus mFOLFOX6. ASCO 2026. Abstract 3576.\n\n11. Telisotuzumab adizutecan plus bevacizumab. Annals of Oncology. 2026.\n\n12. CAPability-01. Nature Medicine. 2024.\n\n13. Vascular Normalization Augments the Anti-tumor… Cancer Discovery. 2025.\n\n14. 安邦生技。ABT-301 臨床進度公告。2026-10-05。\n\n15. ClinicalTrials.gov。ABT-301（NCT07244705）。\n\n16. Hsu TA, et al. Pharmaceutical kits and uses thereof for treating colorectal cancer. US20240277663A1. 2024.\n\n17. Exelixis。STELLAR-303 試驗更新。2026-06-22。\n\n18. Saeed A, et al. STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer. Future Oncology. 2024.\n\n19. Khushalani NI。HBI-8000-303。ESMO 2026；LBA54。KOL Pulse 投影片轉載。\n\n20. National Cancer Institute。HBI-8000＋nivolumab 試驗（NCI-2022-06408）。\n\n21. Michielin O。LBA54 – RESULTS: TOXICITY。ESMO 2026。現場投影片照片（2026-11-11 提供）。\n\n22. FDA。Jemperli 藥品仿單。2026。\n\n23. ESMO Congress 2026。黑色素瘤場次；LBA54。"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"What are the key developments in “On October 19, 2026, the U.S. FDA granted accelerated approval to GSK's Jemperli (dostarlimab), based on AZUR-1 data, for adults with stage II/III locally advanced rectal cancer with deficient mismatch repair or high microsatellite instability (dMMR/MSI-H)”?","a":"On October 19, 2026, the U.S. FDA granted accelerated approval to GSK's Jemperli (dostarlimab), based on AZUR-1 data, for adults with stage II/III locally advanced rectal cancer with deficient mismatch repair or high microsatellite instability (dMMR/MSI-H). Patients receive immunotherapy first. Those who achieve a clinical complete response may, after evaluation, be managed nonoperatively under close surveillance, potentially avoiding surgery and radiation while preserving the rectum. [1]"},{"q":"What are the key developments in “This approval applies to locally advanced dMMR/MSI-H rectal cancer”?","a":"This approval applies to locally advanced dMMR/MSI-H rectal cancer. A different and still largely unsolved challenge is metastatic colorectal cancer that is microsatellite stable and mismatch-repair proficient (MSS/pMMR). Over the past decade, major drugmakers have tested many immunotherapy combinations in this population, but only a handful have improved survival in Phase 3 trials."},{"q":"What are the key developments in “That same month, ESMO 2026 delivered another signal: in a Phase 3 trial in advanced melanoma, an HDAC inhibitor plus a PD-1 antibody improved progression-free survival”?","a":"That same month, ESMO 2026 delivered another signal: in a Phase 3 trial in advanced melanoma, an HDAC inhibitor plus a PD-1 antibody improved progression-free survival. The result adds a piece of evidence to the therapeutic strategy behind Anbogen Therapeutics' ABT-301 triplet and sharpens the central question: can this approach work in MSS colorectal cancer? [8]"}]}